In QUAZAR, the oral formulation was compared to placebo as a maintenance therapy for newly ... rate with current first-line therapies. For BMS, the data positions CC-486 into a segment of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback